Kolyvagin used Heegner points to associate a system of cohomology classes to an elliptic curve over Q and conjectured that the system contains a non-trivial class. His conjecture has profound implications on the structure of Selmer groups. We provide new computational and theoretical evidence for Kolyvagin’s conjecture. More precisely, we explicitly compute Heegner points over ring class fields...

This is an introduction to classical descent theory, in the context of abelian varieties over number fields.

Radioligand therapy (RLT) with Lu-177-labeled PSMA-ligands is a new therapy option for prostate cancer. Biodistribution in normal tissues is of interest for therapy planning. We evaluated if the biodistribution of Ga-68-PSMA-11 is influenced by tumor load. RESULTS In patients with high tumor load, SUVmean was reduced to 61.5% in the lacrimal glands, to 56.6% in the parotid glands, to 63.7% in...

The detection of prostate cancer lesions by PET imaging of the prostate-specific membrane antigen (PSMA) has gained highest clinical impact during the last years. 68Ga-labelled Glu-urea-Lys(Ahx)-HBED-CC ([68Ga]Ga-PSMA-HBED-CC) represents a successful novel PSMA inhibitor radiotracer which has recently demonstrated its suitability in individual first-in-man studies. The radiometal chelator HBED-...

We study monodromy action on abelian varieties satisfying certain bad reduction conditions. These conditions allow us to get some control over the Galois image. As a consequence we verify the Mumford–Tate conjecture for such abelian varieties.

Introduction: Prostate cancer (PC) is the second most commonly diagnosed in males. 68Ga-PSMA PET/CT, a non-invasive diagnostic tool to evaluate PC with prostate-specific membrane antigen (PSMA) expression, has emerged as more accurate alternative assess disease staging. We aimed identify predictors of positive PET and accuracy this technique. Materials methods: Diagnostic cross-sectional study ...

BACKGROUND Radioligand therapy (RLT) with (177)Lu-DKFZ-617 PSMA (Lu-PSMA) (prostate-specific membrane antigen) is a novel targeted therapy of metastatic prostate cancer. We analysed retrospectively the early side effects and the response rate in the first patients, who received a therapy with Lu-PSMA in our departments. METHODS RLT was performed in ten hormone- and/or chemo-refractory patient...